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level targets in a European registry?
A post-hoc analysis of the EUROASPIRE III
for coronary heart disease patientsProduction and hosting by ElsevierFahad Alnouri a,⇑, David Wood b, Kornelia Kotseva c, Mohamed E.A. Ibrahim daCardiovascular Prevention Unit, Prince Sultan Cardiac Centre Riyadh
bGarfield Weston Chair, National Heart and Lung Institute, Imperial College London
cNational Heart and Lung Institute, Imperial College London
dPrevention and Control of Cardiovascular Diseases Department, Ministry of Health
a,d Saudi Arabia
b,cUnited KingdomObjective: The objective of the study is to determine the proportion of patients within the subsample reaching the
target lipid levels defined in the European guidelines, stratified according to type and dose of statin used.
Background: Many factors affect the attainment of lipid level targets including gender, age, compliance, statin
type, and dosage. This study aimed to determine the percentage of post-interventional coronary heart disease
(CHD) patients who met the lipid level targets recommended by the Joint European Societies Guidelines, the med-
ications used, and their doses.
Methods: A post-hoc analysis of a subsample of 2,000 patients from EUROASPIRE III database was selected ran-
domly from patients who attended the interviews (between six months to three years after event). Further stratifica-
tion according to type and dose of statin was performed.
Results: The sample comprised 74.5% males, and two thirds (63.8%) of the entire sample were over 60 years of age.
More women thanmen showed elevated total cholesterol (>4.5 mmol/l and >4.0 mmol/l), LDL-cholesterol (>2.5 mmol/
l and >2.0 mmol/l), and triglycerides (>1.7 mmol/l). Atorvastatin was themost widely used at both discharge and inter-
view (47.1% and 45.4%) than simvastatin (37.7% and 39.4%). A dose of 20 mg atorvastatin was used by 44.10% of
patients, while those on fluvastatin used a higher dose:P40 mg in 88.31%. Patients who achieved targeted total cho-
lesterol levels for atorvastatin, fluvastatin, lovastatin and simvastatin showed a trend in dose increase. Pravastatin
users who achieved the target were taking a dose of 10 mg (75%) and less were in the 20 mg group (33.33%). Rosuvast-
atin users who consumed 10 mg andP40 mg dose achieved the lipid level targets by 61.82% and 66.67%, respectively.
Conclusion: Compliance withmedications was high after a CHD incident in this European sample and the increase
of the atorvastatin and simvastatin doses enabled the attainment of the target levels recommended.
 2014 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.rt diseases, Lipid level, EUROASPIRE III
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Hypercholesterolemia is a preventable riskfactor for several metabolic and chronic
health issues such as coronary heart disease
(CHD). Hypercholesterolemia increases morbidity
and all-cause mortality in patients. According to
previous studies, statins are used extensively in
most European countries with an average
annual increase in the rate of 31% [1]. Recent
estimates suggest that average statin prevalence
for primary prevention of CHD is 86.4%, ranging
from 91.0% in Poland and 75.7% in the Czech
Republic [2].
The impressive results of the Merck-sponsored
Scandinavian Simvastatin Survival Study in the
early 1990s marked the beginning of statin ther-
apy success and popularity, which is still on the
rise [3]. Baigent et al. [4] reviewed 14 randomised
trials including 90,056 patients and concluded that
statin therapy can reduce the five-year incidence
of major coronary events, coronary revasculariza-
tion, and stroke by 21% for every 1.0 mmol/l
reduction in LDL-cholesterol (independent of
patient’s baseline lipid profile or other character-
istics). In addition, statins have been shown to
reduce mortality as well as the need for coronary
artery by-pass, grafting, and coronary angioplasty.
Previous studies demonstrate that administration
of statins in higher doses can stop the progression
or even cause regression of atherosclerosis
thereby reducing the risk of coronary heart dis-
eases [5], and even dementia [6]. Other statins like
rosuvastatin serve dual functions: anti-platelet
activity with lipid lowering benefits [7].
However, varying degrees of intolerability and
toxicity to statins have also been reported in some
patients. The most frequently reported adverse
events include: muscle complaints, gastrointesti-
nal discomfort, elevated liver enzymes, and cogni-
tive and memory problems in less than 5% of
cases [8,9]. Myopathy is reported in 20% of indi-
viduals, making it the most recorded therapy-
associated adverse event [10]. However, a group
of randomised clinical trials which reported a 5%
incidence of myalgia found the same percentage
in the placebo group and concluded that it might
not be drug-related [11].
To record the relevant results with precision,
Sathasivam argued that myalgia, myositis, rhab-
domyolysis, and the asymptomatic increase in cre-
atine kinase concentration (CK) cause confusion
in the reporting of muscle-related events in
research studies. Sathasivam also claimed that
statins cause irreversible necrotizing autoimmune
myopathy [12]. Despite the counter-evidence of itssafety, statins are the second most widely used
medications around the globe.
According to the 2007 guidelines by the Joint
European Societies, total plasma cholesterol levels
should be <5.0 mmol/l, and LDL-cholesterol
should be <3.0 mmol/l. In patients with recog-
nized cardiac risk factors like clinically established
atherosclerosis and diabetes, treatment goals
should be lower (i.e. total cholesterol: <4.5 mmol/
l, with an even lower target of <4.0 mmol/l, if fea-
sible; and LDL-cholesterol: <2.5 mmol/l, with a
target of <2.0 mmol/l). Asymptomatic individuals
with multiple risk factors but recommended
serum cholesterol levels appear to benefit from
further reduction of total cholesterol to
<4.5 mmol/l and LDL-cholesterol to <2.5 mmol/l,
if possible [13].Materials and methods
The methodology of the EUROASPIRE III sur-
vey is fully reported by Kotseva et al. [14]. The sur-
vey was conducted in 76 centres in 22 European
countries. In each country, a single geographical
area and a minimum of two hospitals were
selected and the general practices which referred
to these hospitals were also identified. A random
subsample was selected from the total EUROA-
SPIRE III sample. A further analysis stratified
patients according to gender, age at index event
(<50, 50–59, 60–69 and P70 years), and diagnostic
category (coronary artery by-pass graft (CABG),
percutaneous transluminal coronary angioplasty
(PTCA), acute myocardial infarction (AMI), and
ischaemia). A sub-sample of 2,000 subjects was
calculated as being adequate to estimate the prev-
alence of risk factors with a precision of 5%, and a
confidence interval of 95%.
Study population and inclusion criteria
Individuals aged 18–80 years at the time of iden-
tification presenting to any of the selected hospi-
tals for primary or recurrent clinical diagnosis or
treatments for CHD were retrospectively identi-
fied. The starting date for identification was
P6 months but 63 years prior to the expected
date of interview. Data obtained earlier than Sep-
tember 2003 was not included in the study. All
cases diagnosed in clinical practice were included
in the study population. Included participants had
to fulfil more than one of the following criteria:
I. They had undergone elective or emergency
coronary artery by-pass graft (CABG) opera-
tion, including emergency CABG for acute
myocardial infarction (AMI).
Table 1. Characteristics of the study population by sex, age at
index event and diagnostic category.
Patients records
and interview (n)
Participation rate
at interview (%)
Sex
Men 1490 74.50
Women 510 25.50
Total 2000 100.00
Age at index event
<50 years 180 9.00
50–59 years 544 27.20
60–69 years 744 37.20
P70 years 532 26.60
Total 2000 100.00
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LIPID LEVEL TARGETS IN THE EUROPEAN REGISTRYII. They had undergone elective or emergency
percutaneous transluminal coronary angio-
plasty (PTCA), including emergency PTCA
for AMI.
III. They had AMI (ST elevation and non-ST ele-
vation MI).
IV. They had acute myocardial ischaemia but no
evidence of infarction (Troponin negative).
The study also included subjects who had died
during hospitalization or in surgery. The Local
Research Ethics Committee in each centre
approved the study. A signed informed consent
was obtained from each participant by the
investigators.
Data collection and management
Standardised tools and instruments were
employed to identify the subjects based on the
inclusion criteria, after which interviews and
examinations were conducted by trained
researchers and research assistants. A standard-
ised method was used for collection of blood sam-
ples, and equipments were calibrated according to
the manufacturer’s guidelines. Data auditing were
conducted at local and central levels to assure
attained quality. During the 12-month course of
the EUROASPIRE III study, the coefficient of var-
iation (mean ± SD) and systematic error (bias)
(mean ± SD) were 0.8% ± 0.2 and 0.8% ± 0.5 for
total cholesterol, 2.3% ± 0.6 and 0.6% ± 1.4
for HDL-cholesterol, 1.1% ± 0.4 and 1.1% ± 1.2
for triglycerides, respectively [14].
Outcome measures
The chief outcome measure was the proportion
of patients achieving the target total cholesterol
and LDL-cholesterol levels defined in the Third
and Fourth Joint European Societies Guidelines
on Cardiovascular Disease Prevention in Clinical
Practice [13]. The secondary outcome measure
was the proportion of patients achieving target
total cholesterol levels of <4.5 and <4.0 mmol/l,
according to the type and dose of statin used.
Statistical analyses
All analyses were done using STATA statistical
software release 10 (Stata Corp. LP; Texas, USA).Diagnostic category
CABG 405 20.25
PTCA 818 40.90
AMI 377 18.85
Ischaemia 400 20.00
Total 2000 100.00
AMI, acute myocardial infarction; CABG, coronary artery bypass graft;
PTCA, percutaneous transluminal coronary angioplasty.Results
Study sample and patient characteristics
In the EUROASPIRE III survey, a total of 13,935
medical records were reviewed, and 8966 patients
were interviewed at least six months afteradmission for an acute coronary event or surgical
procedure as defined in the list of inclusion
criteria.
In the analysis reported here, a total of 2000
patients were randomly selected from the whole
EUROASPIRE III survey sample. Characteristics
of this sample are shown in Table 1. Almost three
quarters (74.5%) of the study sample were male,
and one quarter (25.5%) female. Almost two thirds
of patients (63.8%) were aged over 60 years, with
less than one tenth (9%) aged below 50 years.
Over two fifths of patients (40.9%) had a diagnosis
of PTCA, with approximately one fifth of patients
diagnosed with either CABG, AMI or ischaemia
(20.3%, 18.6% and 20.0%, respectively). Participant
attendance at interview in this subsample was
100%.
Lipid profiles of study participants at discharge
and interview
Lipid profiles of patients at discharge are shown
in Table 2, stratified according to sex, age, and
diagnostic category. Stratification according to
age at index event suggests that <50 age group
had the largest proportion of patients with total
cholesterol levels P4.5 mmol/l (74.26%) and
LDL-cholesterol P2.5 mmol/l (77.22%), with the
P70 age group showing the smallest proportion
of patients with similar elevated levels of total
and LDL-cholesterol (62.77% and 67.88%, respec-
tively; Table 2). The 60–69 age group had the high-
est proportion of patients with levels of total
cholesterol P4.0 mmol/l (85.29%) and the P70
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Table 2. Patient total cholesterol, HDL-cholesterol, LDL-cholesterol and triglyceride levels obtained from hospital discharge
documents according to sex, age and diagnostic category.
TCP 4.5 mmol/l
% (n)
TCP 4 mmol/l
% (n)
Decreased
HDL% (n)
LDLP 2.5 mmol/l
% (n)
LDLP 2 mmol/l
% (n)
TG > 1.7 mmol/l
% (n)
Sex
Men 65.55 (529/807) 81.41 (657/807) 68.83 (424/616) 70.85 (435/614) 86.48 (531/614) 25.93 (218/837)
Women 74.67 (224/300) 87.00 (261/300) 58.03 (112/193) 74.75 (148/198) 89.39 (177/198) 31.72 (92/290)
Total with data
available
1107 1107 809 812 812 1127
Age at index event
<50 years 74.26 (75/101) 82.18 (83/101) 63.16 (48/76) 77.22 (61/79) 88.61 (70/79) 23.76 (24/101)
50–59 years 69.14 (224/324) 84.88 (275/324) 64.96 (152/234) 70.43 (162/230) 86.52 (199/230) 31.75 (100/315)
60–69 years 69.12 (282/408) 85.29 (348/408) 68.57 (216/315) 73.87 (229/310) 88.39 (274/310) 28.04 (120/428)
P70 years 62.77 (172/274) 77.37 (212/274) 65.22 (120/184) 67.88 (131/193) 85.49 (165/193) 22.97 (65/283)
Total with data
available
1107 1107 809 812 812 1127
Diagnostic category
CABG 61.49 (99/161) 81.37 (131/161) 63.44 (59/93) 72.04 (67/93) 90.32 (84/93) 23.40 (44/188)
PTCA 65.26 (293/449) 80.85 (363/449) 69.05 (241/349) 68.31 (235/344) 83.72 (288/344) 20.50 (91/444)
AMI 70.12 (176/251) 83.27 (209/251) 62.50 (125/200) 74.88 (155/207) 88.89 (184/207) 34.30 (83/242)
Ischaemia 75.2 (185/246) 87.40 (215/246) 66.47 (11/167) 75.00 (126/168) 90.48 (152/168) 35.97 (91/253)
Total with data
available
1107 1107 809 812 812 1127
HDL <1 mmol/l (men). HDL <1.2 mmol/l (women).
AMI, acute myocardial infarction; CABG, coronary artery bypass graft; HDL, high-density lipoprotein; LDL, low-density lipoprotein; PTCA, percu-
taneous transluminal coronary angioplasty; TC, total cholesterol; TG, triglycerides.
⁄Some patient case notes contained incomplete information.
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had the highest proportion of patients with levels
of LDL-cholesterol P2.0 mmol/l (88.61%), and the
P70 age group the lowest (85.49%). The 60–69 age
group had the highest proportion of patients with
decreased HDL-cholesterol levels (68.57%), with
the <50 age group having the lowest (63.16%).
The 50–59 age group had the greatest proportion
of patients with triglycerides P1.7 mmol/l
(31.75%) while the P70 age group had the lowest
(22.97%).
Lipid profiles of patients at interview/examina-
tion are shown in Table 3, stratified according to
sex, age, and diagnostic category. For total choles-
terol and LDL-cholesterol, there was a trend
towards a lower proportion of patients in each
group with elevated serum cholesterol levels. A
similar positive trend was also observed for
decreased HDL-cholesterol levels. However, the
converse was true for triglycerides, with a higher
proportion of patients demonstrating raised levels
(P1.7 mmol/l) at interview versus discharge.
When stratified according to sex, a greater propor-
tion of women showed elevated levels of total cho-
lesterol (P4.5 mmol/l), LDL-cholesterol
(P2.5 mmol/l) and triglycerides (P1.7 mmol/l)
compared with men in the study sample.
Stratification according to diagnostic category
showed that the ischaemia group had the highestproportion of patients with total cholesterol levels
P4.5 mmol/l and LDL-cholesterol levels
P2.5 mmol/l (58.55% and 62.95%, respectively).
The PTCA group had the lowest proportion of
patients with elevated serum levels of these
(46.99% and 48.97%, respectively). The CABG
group had the highest proportion, and the AMI
group the lowest proportion of patients with both
decreased levels of HDL-cholesterol and raised
triglyceride levels (65.85% versus 59.38%).Use of lipid lowering medication and therapeutic
control of total cholesterol levels
Use of lipid lowering medication by patients in
the study sample and level of therapeutic control
of total cholesterol levels at interview are shown
in Table 4. Approximately one fifth of both men
and women in the sample were using no lipid low-
ering medication (20.38% vs. 21.74%, respectively).
Slightly more men than women were able to
achieve the target total cholesterol levels of <4.5
and <4.0 mmol/l in this group. Of the four fifths
of both men and women who were using lipid
lowering medication, a higher proportion of men
than women achieved the recommended target
of total cholesterol levels for Europe (<4.5 mmol/
l: 58.61% vs. 43.57%; <4.0 mmol: 39.47% vs.
23.62%) [15].
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Table 3. Patient total cholesterol, HDL-cholesterol, LDL-cholesterol and triglyceride levels obtained at interview/examination
according to sex, age and diagnostic category.
TCP 4.5 mmol/l
% (n)
TCP 4 mmol/l
% (n)
Decreased
HDL% (n)
LDLP 2.5 mmol/l
% (n)
LDLP 2 mmol/l
% (n)
TG < 1.7 mmol/l
% (n)
Sex
Men 47.94 (664/1385) 65.42 (906/1385) 64.19 (889/1385) 51.65 (562/1088) 76.56 (833/1088) 32.38 (362/1118)
Women 61.51 (302/491) 79.23 (389/491) 55.60 (273/491) 61.50 (222/361) 82.83 (299/361) 34.86 (129/370)
Total with data
available
1876 1876 1876 1449 1449 1488
Age at index event
<50 years 51.45 (89/173) 64.74 (112/173) 52.60 (91/173) 53.28 (73/137) 78.83 (108/137) 35.37 (52/147)
50–59 years 54.91 (274/499) 70.74 (353/499) 58.72 (293/499) 57.64 (230/399) 79.20 (316/399) 37.96 (156/411)
60–69 years 50.72 (352/694) 68.59 (476/694) 65.85 (457/694) 51.50 (275/534) 77.15 (412/534) 33.09 (180/544)
P70 years 49.22 (251/510) 69.41 (354/510) 62.94 (321/510) 54.35 (206/379) 78.10 (296/379) 26.68 (103/386)
Total with data
available
1876 1876 1876 1449 1449 1488
Diagnostic category
CABG 50.68 (187/369) 67.48 (249/369) 65.85 (243/369) 52.69 (147/279) 74.91 (209/279) 37.15 (107/288)
PTCA 46.99 (359/764) 65.18 (498/764) 61.91 (473/764) 48.97 (310/633) 75.51 (478/633) 33.90 (220/649)
AMI 54.34 (194/357) 70.87 (253/357) 59.38 (212/357) 59.09 (169/286) 80.07 (229/286) 27.89 (82/294)
Ischaemia 58.55 (226/386) 76.42 (295/386) 60.62 (234/386) 62.95 (158/251) 86.06 (216/251) 31.91 (82/257)
Total with data
available
1876 1876 1876 1449 1449 1488
HDL <1 mmol/l (men). HDL <1.2 mmol/l(women).
AMI, acute myocardial infarction; CABG, coronary artery bypass graft; HDL, high-density lipoprotein; LDL, low-density lipoprotein; PTCA, percu-
taneous transluminal coronary angioplasty; TC, total cholesterol; TG, triglycerides.
⁄Interview data from some patients incomplete.
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similar proportions of patients in the <50, 50–59,
and 60–69 age groups were using no lipid lowering
medications (18.44%, 18.11% and 17.77%, respec-
tively). However, this figure was higher in the
P70 age group (28.25%). The proportion of
patients across all groups achieving the target
total cholesterol level of <4.0 mmol/l was much
lower (Table 4).
When stratified by diagnostic category, consid-
erable between-group variation in the use of lipid
lowering medication could be observed, with the
highest proportion of patients using no medica-
tion seen in the ischaemia group (31.99%), and
the lowest in the PTCA group (13.87%). Variation
was also seen in the proportion of those patients
using no lipid lowering medication but able to
achieve the target total cholesterol levels of <4.5
and <4.0 mmol/l. The highest proportions of
patients achieving these targets were in the
ischaemia group (29.51% and 16.39%, respec-
tively), while the lowest proportions achieving
<4.5 and <4.0 mmol/l were in the AMI and CABG
groups, respectively (18.75% vs. 11.11%). Of those
patients using lipid lowering medication, a similar
proportion in the CABG, PTCA and AMI groups
were able to achieve the target of <4.5 mmol/l
(Table 4). A lower proportion of patients in the
ischaemia group achieved both target goals.At interview, the proportions of patients using
medications were similar across the <50, 50–59
and 60–69 age groups (81.56%, 81.89% and
82.23%, respectively), but lower in the P70 age
group (71.75%). When stratified by diagnostic cat-
egory, the highest proportion of patients using
lipid lowering medication at discharge was in the
PTCA group (89.70%) and the lowest in the ischae-
mia group (75.52%). A similar trend was also
observed at interview (Table 5).
The vast majority of patients (98.44%) using lipid
lowering medications were taking statins (98% of
men and 99% of women; Table 5) as opposed to
1.6% using other lipid lowering medication at dis-
charge, including fibrates, nicotinic acid, choles-
terol absorption inhibitors and resins (Table 6).
Data on the number of patients using each of
these medications are not shown. At both dis-
charge and interview, statin use trends across all
subgroups closely mirrored those for lipid lower-
ing medication (Table 5).Types of statin used and level of therapeutic
control according to type of statin and dose
The six statins used by patients in the subsam-
ple were atorvastatin, fluvastatin, lovastatin, prav-
astatin, rosuvastatin and simvastatin. Atorvastatin
was the most widely used at both discharge and
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Table 4. Therapeutic control of serum cholesterol at interview by sex, age and diagnostic category.
No lipid-lowering
medication % (n)
No lipid-
lowering
medication
reaching goal
TC < 4.5 mmol/l
% (n)
No lipid-
lowering
medication
reaching goal
TC < 4 mmol/l
% (n)
Lipid-
lowering
medication
% (n)
Lipid-lowering
medication
reaching goal
TC < 4.5 mmol/l
% (n)
Lipid-lowering
medication
reaching goal
TC < 4 mmol/l
% (n)
Sex
Men 20.38 (302/1482) 26.69 (75/281) 15.66 (44/281) 79.62 (1180/
1482)
58.61 (643/1097) 39.47 (433/1097)
Women 21.74 (110/506) 20.56 (22/107) 10.28 (11/107) 78.26 (396/
506)
43.57 (166/381) 23.62 (90/381)
Total data available 1988 388 388 1988 1478 1478
Age at index event
<50 years 18.44 (33/179) 12.50 (4/32) 9.38 (3/32) 81.56 (146/
179)
56.43 (79/140) 40.71 (57/140)
50–59 years 18.11 (98/541) 24.73 (23/93) 18.28 (17/93) 81.89 (443/
541)
49.88 (202/405) 31.85 (129/405)
60–69 years 17.77 (1311/737) 27.27 (33/121) 15.70 (19/121) 82.23 (606/
737)
54.24 (307/566) 34.98 (198/566)
P70 years 28.25 (150/531) 26.06 (37/142) 11.27 (16/142) 71.75 (381/
531)
60.22 (221/367) 37.87 (139/367)
Total data available 1988 388 388 1988 1478 1478
Diagnostic category
CABG 17.87 (72/403) 20.63 (13/63) 11.11 (7/63) 82.13 (331/
403)
54.93 (167/304) 36.84 (112/304)
PTCA 13.87 (113/815) 28.04 (30/107) 15.89 (17/107) 86.13 (702/
815)
57.01 (374/656) 37.80 (248/656)
AMI 26.81 (100/373) 18.75 (18/96) 11.46 (11/96) 73.19 (273/
373)
56.03 (144/257) 35.80 (92/257)
Ischaemia 31.99 (127/397) 29.51 (36/122) 16.39 (20/122) 68.01 (270/
397)
47.51 (124/261) 27.20 (71/261)
Total data available 1988 388 388 1988 1478 1487
AMI, acute myocardial infarction; CABG, coronary artery bypass graft; PTCA, percutaneous transluminal coronary angioplasty, TC, total cholesterol.
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tively). This was followed by simvastatin (37.7%
vs. 39.4% of patients, respectively). Levels of use
of the other statins were much lower (<10% of
patients using each at both discharge and inter-
view) (Table 7).
The distribution of the different daily doses
used by patients for each statin is shown in
Table 8. Atorvastatin, pravastatin, rosuvastatin
and simvastatin were all used at daily doses of
10, 20 or P40 mg, while fluvastatin and lovastatin
were used at doses of 20 or P40 mg. The most
commonly used dose of atorvastatin was 20 mg
(used by 44.10% of study subsample), with a lower
number of patients taking other doses. The vast
majority of patients using fluvastatin were taking
doses of P40 mg (88.31%), with a small number
taking the 20 mg dose (7.79%).
The proportion of patients who achieved target
total cholesterol levels of <4.5 and <4.0 mmol/l is
shown in Table 8. For atorvastatin, a trend of
achieving the target by increasing dosage was
observed for both target total cholesterol levels,with similar trends observed with fluvastatin, lov-
astatin and simvastatin. With pravastatin, the
highest proportion of patients achieving the target
of <4.5 mmol/l was seen in the group taking a dose
of 10 mg (75.00%) and the lowest in the 20 mg
group (33.33%). With rosuvastatin, the highest
proportion of patients achieved the <4.5 mmol/l
target in P40 mg dose group and the lowest was
in the 20 mg group. A different trend was
observed in the proportion of patients achieving
the lower 4.0 mmol/l target, with the highest pro-
portion in the 10 mg group and the lowest in
20 mg group. As expected, the portion of patients
achieving the <4.0 mmol/l target was considerably
lower than the portion achieving the <4.5 mmol/l
target.
When considering the proportion of patients
achieving the recommended target total choles-
terol across all statin subgroups, it can be seen
that, overall, the highest proportions of patients
achieving these targets were in the atorvastatin
and rosuvastatin groups, while the lowest was in
the fluvastatin group.
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Table 5. Reported use of lipid lowering medications at discharge and interview by sex, age and diagnostic category.
Lipid-lowering medication%(n) Lipid-lowering medication%(n) Statins % (n) Statins % (n)
D I D I
Sex
Men 80.59 (1171/1453) 79.62 (1180/1482) 79.35 (1153/1453) 78.21 (1159/1482)
Women 79.56 (397/499) 78.26 (396/506) 79.16 (395/499) 76.63 (387/505)
Total data available 1952 1988 1952 1987
Age at index event
<50 years 88.44 (153/173) 81.56 (146/179) 87.28 (151/173) 80.45 (144/179)
50–59 years 84.59 (450/532) 81.89 (443/541) 83.46 (444/532) 80.56 (435/540)
60–69 years 79.28 (574/724) 82.23 (606/737) 77.90 (564/724) 80.19 (591/737)
P70 years 74.76 (391/523) 71.75 (381/531) 74.38 (389/523) 70.81 (376/531)
Total data available 1952 1988 1952 1987
Diagnostic category
CABG 70.43 (281/399) 82.13 (331/403) 70.18 (280/399) 81.14 (327/403)
PTCA 89.70 (714/796) 86.13 (702/815) 88.57 (705/796) 84.52 (688/814)
AMI 75.88 (280/369) 73.19 (273/373) 75.34 (278/369) 71.85 (268/373)
Ischaemia 75.52 (293/388) 68.01 (270/397) 73.45 (285/388) 66.25 (263/397)
Total data available 1952 1988 1952 1987
D, discharge; I, interview.
Table 7. Use of statins by generic name at discharge and
interview.
Statin Discharge (n) % Interview (n) %
Atorvastatin 729 47.1 702 45.4
Fluvastatin 101 6.5 78 5.0
Lovastatin 18 1.2 15 1.0
Pravastatin 56 3.6 51 3.3
Rosuvastatin 60 3.9 91 5.9
Simvastatin 583 37.7 608 39.4
Total 1547 100 1545 100
Table 6. Types of lipid-lowering medications used at interview.
(n) %
Statin 1956 98.44
Other 31 1.56
1987 100.00
J Saudi Heart Assoc
2014;26:183–191
ALNOURI ET AL 189
LIPID LEVEL TARGETS IN THE EUROPEAN REGISTRYDiscussion
Despite the controversies about statins and the
worrying fact that physicians prescribe them to
reduce the CVD risk by 30%, one third of patients
achieved the desired lipid targets of <4.5 mmol/l
without using medications. This study confirmed
the pre-existing evidence that statins were the
most used lipid lowering agents, with less than
2% taking other types of medications. Besides, a
trend of increasing statin use was observed over
the study period, with a median annual increase
of 35.6%. Moreover, atorvastatin and simvastatin
are emphasized as the market leaders in their
category.
It was also observed that drug use compliance
decreases with time despite the fact that manypopulation-based cohort studies emphasize that
patients who do not use statins after an AMI have
higher total one-year mortality [16]. Therefore,
patient knowledge on this subject and the quality
of follow-up and recommendations by their treat-
ing doctors has to be investigated.
One result was in contrast to some studies [17].
This was the controversial conclusion that more
senior patients used statins after six months to
three years of an event. Furthermore, ischaemia
patients were the largest group not using medica-
tions (31.99%) yet the highest proportions of
patients achieving the targets of <4.5 and
<4.0 mmol/l were in that group (29.51% and
16.39%, respectively). Does this imply that fewer
medications are required for ischemic patients?
This question needs further analysis.
The current study is no exception in proving
that atorvastatin achieves the desired targets by
increasing the dose as well as simvastatin. How-
ever, this should be interpreted with caution due
to the small number of patients in each group.
These results contradict those of the EUROA-
SPIRE II study, which showed a decrease in the
proportion of patients reaching the target total
cholesterol level of <5.0 mmol/l with increasing
doses of atorvastatin and simvastatin. Yet the
findings of this study are in line with other studies
such as Bonnet et al.’s multicentre, prospective,
randomised, double-blind, double-dummy study
in 339 patients with CHD. With a compelling level
of evidence, this study showed that a high 80 mg
dose of atorvastatin versus the usual dose of
10 mg facilitated the attainment of the targeted
lower levels of lipid profile [18]. Similarly, a
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Table 8. Proportion of patients achieving target total cholesterol level stratified by type of statin and dose.
Distribution of statins according
to actual daily dose (%)
TC < 4.5 mmol/l % (n) TC < 4 mmol/l % (n)
Atorvastatin 10 mg 25.91 56.47 (96/170) 34.71 (59/170)
Atorvastatin 20 mg 44.10 59.79 (168/281) 38.43 (108/281)
Atorvastatin P40 mg 28.7 65.45 (125/191) 48.69 (93/191)
Fluvastatin 20 mg 7.79 16.67 (1/6) 16.67 (1/6)
Fluvastatin P40 mg 88.31 38.71 (24/62) 17.74 (11/62)
Lovastatin 20 mg 60.00 33.33 (3/9) 22.22 (2/9)
Lovastatin P40 mg 33.33 60.00 (3/5) 40.00 (2/5)
Pravastatin 10 mg 8.00 75.00 (3/4) 25.00 (1/4)
Pravastatin 20 mg 40.00 33.33 (6/18) 22.22 (4/18)
Pravastatin P40 mg 50.00 56.52 (13/23) 26.09 (6/23)
Rosuvastatin 10 mg 68.89 61.82 (34/55) 40.00 (22/55)
Rosuvastatin 20 mg 18.89 50.00 (8/16) 25.00 (4/16)
Rosuvastatin P40 mg 5.56 66.67 (2/3) 33.33 (1/3)
Simvastatin 10 mg 12.85 43.84 (32/73) 21.92 (16/73)
Simvastatin 20 mg 50.25 49.65 (140/282) 31.56 (89/282)
Simvastatin P40 mg 35.39 56.63 (111/196) 41.84 (82/196)
TC, total cholesterol.
⁄Some patient data on statin dose taken missing.
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dose (80 mg) versus low dose (20 mg) simvastatin
found a strong dose-related response for changes
in total (p < 0.01) and LDL-cholesterol (p < 0.001),
with the high-dose regimen achieving a signifi-
cantly greater reduction in serum cholesterol lev-
els than the usual simvastatin dose [19]. Such
evidence serves to encourage more prescriptions
of these drugs [20].
Several studies have debated the Friedewald
formula used in EUROASPIRE III, with some sug-
gesting its results are an underestimation of LDL
levels, whilst others suggest the opposite [21].
Although the EUROASPIRE survey protocol did
not require the use of fasting serum samples for
analysis, only 36 out of 2000 (1.8%) patients in
the subsample analysed in this research had tri-
glyceride levels >4.52 mmol/l, suggesting that the
likelihood of under or overestimation of LDL-cho-
lesterol levels is small for the vast majority of
patients.Conclusions
As a detailed review on the types and doses of
medications able to achieve the desired targets
of blood lipid levels, this study adds to existing
published evidence. Such information is crucial
to a representative sample of all Europe in a study
with excellent data quality. Despite some contro-
versial results, the variation in compliance to med-
ications by age, gender and type of CHD event is
significant and worth stating. The study confirms
the pre-existing evidence that using statins alone
is not enough to achieve target lipid levels.Physicians and patients must be aware of using
only the doses and types that suit patient condi-
tions in order to lead to optimum results.
The fact that the effects of statins are greatly
influenced by the type of the initial vascular event
needs further investigation. Moreover, the pre-
scription behaviour of statins considering their
registered adverse effects needs review (physician
prescription).References
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